ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

INZY Inozyme Pharma Inc

4.74
0.00 (0.00%)
Pre Market
Last Updated: 12:00:04
Delayed by 15 minutes
Share Name Share Symbol Market Type
Inozyme Pharma Inc NASDAQ:INZY NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.74 4.51 5.10 0 12:00:04

Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

05/09/2023 1:30pm

GlobeNewswire Inc.


Inozyme Pharma (NASDAQ:INZY)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Inozyme Pharma Charts.

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman of the board, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, from 12:00-12:30pm ET.

A live webcast of the presentation can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.

About Inozyme Pharma

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. Inozyme is developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.For more information, please visit www.inozyme.com and follow us on LinkedIn, X (formerly Twitter), and Facebook.

ContactsInvestors:Inozyme PharmaStefan Riley, Director of IR and Corporate Communications(857) 330-8871stefan.riley@inozyme.comMedia:SmithSolveMatt Pera(973) 886-9150matt.pera@smithsolve.com

1 Year Inozyme Pharma Chart

1 Year Inozyme Pharma Chart

1 Month Inozyme Pharma Chart

1 Month Inozyme Pharma Chart

Your Recent History

Delayed Upgrade Clock